Toru Yoshimitsu
Director/Miembro de la Junta en OCATA THERAPEUTICS INC .
Cargos activos de Toru Yoshimitsu
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| OCATA THERAPEUTICS INC | Director/Miembro de la Junta | - | - |
Historial de carrera de Toru Yoshimitsu
Antiguos cargos conocidos de Toru Yoshimitsu.
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
Astellas Pharma Europe Ltd.
 Astellas Pharma Europe Ltd. Pharmaceuticals: MajorHealth Technology Astellas Pharma Europe Ltd. engages in the development and sale of pharmaceutical products. The company is headquartered in Addlestone, the United Kingdom. | Director/Miembro de la Junta | 01/04/2017 | 31/03/2020 |
| AUDENTES THERAPEUTICS, INC. | Director/Miembro de la Junta | 15/01/2020 | - |
Estadísticas
Internacional
| Estados Unidos | 3 |
| Reino Unido | 2 |
Operativa
| Director/Board Member | 3 |
Sectorial
| Health Technology | 4 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
| Empresas privadas | 3 |
|---|---|
Astellas Pharma Europe Ltd.
Astellas Pharma Europe Ltd. Pharmaceuticals: MajorHealth Technology Astellas Pharma Europe Ltd. engages in the development and sale of pharmaceutical products. The company is headquartered in Addlestone, the United Kingdom. | Health Technology |
Astellas Gene Therapies, Inc.
 Astellas Gene Therapies, Inc. BiotechnologyHealth Technology Astellas Gene Therapies, Inc. is a biotechnology company, which engages in the development and commercialization of gene therapy products for patients with serious and rare diseases caused by single gene defects. The company was founded by Matthew R. Patterson and Thomas J. Schuetz on November 13, 2012 and is headquartered in San Francisco, CA. | Health Technology |
Astellas Institute for Regenerative Medicine
 Astellas Institute for Regenerative Medicine Pharmaceuticals: MajorHealth Technology Astellas Institute for Regenerative Medicine engages in the development and commercialization of human pluripotent stem cell technology in the field of regenerative medicine. The company also have a preclinical development pipeline in areas outside of ophthalmology, including; autoimmune diseases, inflammatory diseases, and wound healing. The company was founded on May 18, 2000 and is headquartered in Marlborough, MA. | Health Technology |
- Bolsa de valores
- Insiders
- Toru Yoshimitsu
- Experiencia
